Mesoblast Limited

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) One of Singapore's leading private healthcare providers, Parkway Group Healthcare Pte Ltd, a subsidiary of Parkway Holdings Limited, and Australian regenerative medicine company, Mesoblast Limited, today announced a collaborative program to facilitate commercialisation of Mesoblast's proprietary "off-the-shelf" stem cell products within the extensive ParkwayHealth hospital network in Asia.

Australian shares yesterday closed higher after the lift of commodities prices. The benchmark S&P/ASX200 index was up 38.4 points, or 1.08 per cent, at 3,589.3, while the broader All Ordinaries index advanced 36.1 points, or 1.03 per cent, to 3,531 after a positive lead from Wall Street on Friday.

Regenerative Stem Cell/medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) announced that it had received Australian institutional ethics approval to begin the first trial of adult stem cell treatment for prevention of knee osteoathritis.

Regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) announced today that it has received the 2009 Frost & Sullivan Emerging Company Award in the United States Soft Tissue Repair market.

Today I would like to present you with a snapshot of the considerable achievements made by Mesoblast in the 2008 financial year, achievements that cannot be underestimated as the Company moves closer to productisation of its unique adult stem cell platform technology. Later in this meeting, our Executive Director, Professor Silviu Itescu, will detail our progress and plans towards becoming a market leader in our core activities.

Regenerative medicine company, Mesoblast Limited (ASX:MSB;USOTC:MBLTY), announced today that its adult stem cell technology platform has been awarded the 2008 Frost & Sullivan United States Stem Cell Market Technology Innovation of the Year.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced today that the thirteenth patient enrolled in the ongoing Phase 2 clinical trial for congestive heart failure had been safely implanted with the proprietary adult stem cells during a live case at the American Heart Association's annual conference, currently underway in New Orleans.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), is featured today at the 2008 UBS Australian Healthcare Conference underway in Sydney as one of three leading emerging companies in the biotechnology space.

Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the commencement of a Phase I/II clinical trial in the United States using the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in up to 30 patients with haematologic malignancies undergoing bone marrow transplantation.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced successful early safety results in the world's first clinical trial to use allogeneic, or "off-the-shelf", adult stem cells from an unrelated donor to treat patients with congestive heart failure.